Regenxbio is pitching at FDA approval next year for its Duchenne muscular dystrophy (DMD) gene therapy RGX-202, after ...

Biogen has decided to advance its tau-targeting Alzheimer's disease drug diranersen (BIIB080) into a phase 3 trial programme, despite a phase 2 trial missing its main efficacy measure. In the 18-month ...

Cardiac rhythm management is undergoing a significant shift. For decades, cardiac resynchronisation therapy has helped restore synchrony in patients with heart failure and electrical conduction ...

It’s safe to say that AI has firmly captured the interest of decision-makers across the industry. But, as the space continues ...

Immune cell therapies have transformed the treatment of certain blood cancers over the past decade. However, when it comes to ...